Journal of Oncology / 2022 / Article / Tab 1 / Review Article
Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials Table 1 Ramucirumab double-blind phase 3 RCTs.
Study Cancer typesTreatment exposure Sample size Trial registry number Collection time RAINBOW-Asia [27 ] Advanced gastric or GEJ adenocarcinoma RAM 8 mg/kg (days 1 and 15) + paclitaxel VS. PBO + paclitaxel 294/146 NCT02898077 2017.03.02 ∼ 2020.06.30 RELAY [28 ] Advanced NSCLC RAM 10 mg/kg (IV; Q2W) + erlotinib VS. PBO + erlotinib 224/225 NCT02411448 2016.01.28 ∼ 2018.02.1 REACH-2 [29 ] Advanced HCC RAM 8 mg/kg (IV; Q2W) after sorafenib + BSC VS. PBO after sorafenib + BSC 197/95 NCT02435433 2015.07.26 ∼ 2017.08.30 RANGE [30 ] Locally advanced or metastatic UC RAM 10 mg/kg + docetaxel 60 or 75 mg/m2 (IV; day 1, 21-day cycle) VS. PBO + docetaxel 263/267 NCT02426125 2015.07.20 ∼ 2017.04.04 RAINFALL [31 ] Metastatic gastric or junctional adenocarcinoma RAM 8 mg/kg (IV; days 1 and 8, Q21D) + cisplatin + capecitabine VS. PBO + cisplatin + capecitabine 326/319 NCT02314117 2015.01.28 ∼ 2016.09.16 RAINBOW [32 ] Advanced gastric or GEJ adenocarcinoma RAM 8 mg/kg (IV; days 1 and 15) + paclitaxel VS. PBO + paclitaxel 330/335 NCT01170663 2010.12.02 ∼ 2012.09.23 RAISE [33 ] Metastatic colorectal carcinoma RAM 8 mg/kg (IV; day 1, Q2W) + FOLFIRI VS. PBO + FOLFIRI 536/536 NCT01183780 2010.12.14 ∼ 2013.08.23 REVEL [34 ] Stage IV non-small cell lung cancer RAM 10 mg/kg + docetaxel (IV; day 1, 21-day cycle) VS. PBO + docetaxel 628/625 NCT01168973 2010.12.03 ∼ 2013.01.24 REACH [35 ] Advanced hepatocellular carcinoma RAM 8 mg/kg (IV; Q2W) after sorafenib + BSC VS. PBO after sorafenib + BSC 283/282 NCT01140347 2010.11.04 ∼ 2013.04.18 REGARD [36 ] Advanced gastric or GEJ adenocarcinoma RAM 8 mg/kg (IV; Q2W) after chemotherapy + BSC VS. PBO after chemotherapy + BSC 238/117 NCT00917384 2009.10.06 ∼ 2012.01.26 ROSE/TRIO-012 [37 ] Metastatic breast cancer RAM 10 mg/kg + docetaxel (IV; Q3W) VS. PBO + docetaxel 759/385 NCT00703326 2008.08 ∼ 2011.12
RCTs = randomized controlled trials, GEJ = gastroesophageal junction, UC = urothelial carcinoma, RAM = ramucirumab, PBO = placebo, VS. = versus, FOLFIRI = leucovorin (folinic acid), fluorouracil, and irinotecan, BSC = best supportive care, IV = intravenous, Q2W = every 2 weeks, Q3W = every 3 weeks, and Q21D = every 21 days.
